APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide CXO

Peptide CXO covers outsourced research, process development and manufacturing for peptide programmes, from research material and analytical work to clinical and commercial supply.

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide CXO Market Analysis and Forecast 2026-2032

23 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide CXO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide CXO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide CXO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide CXO Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide CXO Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Peptide CXO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptide CXO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide CXO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide CXO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide CXO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peptide CXO include Chinese Peptide Company, WuXi AppTec, Shenzhen JYMed Technology, ReaLi Tide Biological Technology, Jiangsu Sinopep-Allsino Biopharmaceutical, LONZA, Asymchem, GL Biochem and Chengdu Shengnuo Biotechnology, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptide CXO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide CXO, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide CXO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide CXO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide CXO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptide CXO revenue, projected growth trends, production technology, application and end-user industry.

Peptide CXO Segment by Company

Chinese Peptide Company

WuXi AppTec

Shenzhen JYMed Technology

ReaLi Tide Biological Technology

Jiangsu Sinopep-Allsino Biopharmaceutical

LONZA

Asymchem

GL Biochem

Chengdu Shengnuo Biotechnology

AmbioPharm

Polypeptide

Pepscan

JPT Peptide

Bicycle

Bachem

Peptide CXO Segment by Type

CRO

CMO/CDMO

Peptide CXO Segment by Application

Pharmaceutical Companies

Biotech Companies and Research Institutions

Peptide CXO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CXO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide CXO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CXO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptide CXO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptide CXO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CXO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide CXO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CRO Major Player Table 3. CMO/CDMO Major Player Table 4. Global Peptide CXO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Companies Major Player Table 6. Biotech Companies and Research Institutions Major Player Table 7. Peptide CXO Industry Trends Table 8. Peptide CXO Industry Drivers Table 9. Peptide CXO Industry Opportunities and Challenges Table 10. Peptide CXO Industry Restraints Table 11. Global Peptide CXO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Peptide CXO Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Peptide CXO Market Share by Region (2021-2026) Table 14. Global Peptide CXO Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Peptide CXO Market Share by Region (2027-2032) Table 16. Global Peptide CXO Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Peptide CXO Revenue Market Share by Players (2021-2026) Table 18. Global Peptide CXO Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Peptide CXO Key Players Headquarters & Area Served Table 20. Global Peptide CXO Players, Product Type & Application Table 21. Global Peptide CXO Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Peptide CXO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Peptide CXO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Peptide CXO Revenue Market Share by Type (2021-2026) Table 28. Global Peptide CXO Revenue Market Share by Type (2027-2032) Table 29. Global Peptide CXO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Peptide CXO Revenue Market Share by Application (2021-2026) Table 33. Global Peptide CXO Revenue Market Share by Application (2027-2032) Table 34. Chinese Peptide Company Company Information Table 35. Chinese Peptide Company Business Overview Table 36. Chinese Peptide Company Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Chinese Peptide Company Peptide CXO Product Portfolio Table 38. Chinese Peptide Company Recent Development Table 39. WuXi AppTec Company Information Table 40. WuXi AppTec Business Overview Table 41. WuXi AppTec Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. WuXi AppTec Peptide CXO Product Portfolio Table 43. WuXi AppTec Recent Development Table 44. Shenzhen JYMed Technology Company Information Table 45. Shenzhen JYMed Technology Business Overview Table 46. Shenzhen JYMed Technology Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Shenzhen JYMed Technology Peptide CXO Product Portfolio Table 48. Shenzhen JYMed Technology Recent Development Table 49. ReaLi Tide Biological Technology Company Information Table 50. ReaLi Tide Biological Technology Business Overview Table 51. ReaLi Tide Biological Technology Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. ReaLi Tide Biological Technology Peptide CXO Product Portfolio Table 53. ReaLi Tide Biological Technology Recent Development Table 54. Jiangsu Sinopep-Allsino Biopharmaceutical Company Information Table 55. Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview Table 56. Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Product Portfolio Table 58. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Development Table 59. LONZA Company Information Table 60. LONZA Business Overview Table 61. LONZA Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. LONZA Peptide CXO Product Portfolio Table 63. LONZA Recent Development Table 64. Asymchem Company Information Table 65. Asymchem Business Overview Table 66. Asymchem Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Asymchem Peptide CXO Product Portfolio Table 68. Asymchem Recent Development Table 69. GL Biochem Company Information Table 70. GL Biochem Business Overview Table 71. GL Biochem Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. GL Biochem Peptide CXO Product Portfolio Table 73. GL Biochem Recent Development Table 74. Chengdu Shengnuo Biotechnology Company Information Table 75. Chengdu Shengnuo Biotechnology Business Overview Table 76. Chengdu Shengnuo Biotechnology Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Chengdu Shengnuo Biotechnology Peptide CXO Product Portfolio Table 78. Chengdu Shengnuo Biotechnology Recent Development Table 79. AmbioPharm Company Information Table 80. AmbioPharm Business Overview Table 81. AmbioPharm Peptide CXO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. AmbioPharm Peptide CXO Product Portfolio Table 83. AmbioPharm Recent Development Table 84. Polypeptide Company Information Table 85. Polypeptide Business Overview Table 86. Polypeptide Peptide CXO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Polypeptide Peptide CXO Product Portfolio Table 88. Polypeptide Recent Development Table 89. Pepscan Company Information Table 90. Pepscan Business Overview Table 91. Pepscan Peptide CXO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Pepscan Peptide CXO Product Portfolio Table 93. Pepscan Recent Development Table 94. JPT Peptide Company Information Table 95. JPT Peptide Business Overview Table 96. JPT Peptide Peptide CXO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. JPT Peptide Peptide CXO Product Portfolio Table 98. JPT Peptide Recent Development Table 99. Bicycle Company Information Table 100. Bicycle Business Overview Table 101. Bicycle Peptide CXO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Bicycle Peptide CXO Product Portfolio Table 103. Bicycle Recent Development Table 104. Bachem Company Information Table 105. Bachem Business Overview Table 106. Bachem Peptide CXO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Bachem Peptide CXO Product Portfolio Table 108. Bachem Recent Development Table 109. North America Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Peptide CXO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Peptide CXO Revenue by Country (2021-2026) & (US$ Million) Table 115. North America Peptide CXO Revenue by Country (US$ Million) & (2027-2032) Table 116. Europe Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 117. Europe Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 118. Europe Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 119. Europe Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 120. Europe Peptide CXO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Peptide CXO Revenue by Country (2021-2026) & (US$ Million) Table 122. Europe Peptide CXO Revenue by Country (US$ Million) & (2027-2032) Table 123. China Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 124. China Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 125. China Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 126. China Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 128. Asia Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 129. Asia Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 130. Asia Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Peptide CXO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Peptide CXO Revenue by Region (US$ Million) & (2021-2026) Table 133. Asia Peptide CXO Revenue by Region (US$ Million) & (2027-2032) Table 134. SAMEA Peptide CXO Revenue by Type (2021-2026) & (US$ Million) Table 135. SAMEA Peptide CXO Revenue by Type (2027-2032) & (US$ Million) Table 136. SAMEA Peptide CXO Revenue by Application (2021-2026) & (US$ Million) Table 137. SAMEA Peptide CXO Revenue by Application (2027-2032) & (US$ Million) Table 138. SAMEA Peptide CXO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. SAMEA Peptide CXO Revenue by Country (2021-2026) & (US$ Million) Table 140. SAMEA Peptide CXO Revenue by Country (US$ Million) & (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Peptide CXO Image Figure 2. Global Peptide CXO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide CXO Market Size Share 2021 VS 2025 VS 2032 Figure 4. CRO Image Figure 5. CMO/CDMO Image Figure 6. Global Peptide CXO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Peptide CXO Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Companies Image Figure 9. Biotech Companies and Research Institutions Image Figure 10. Global Peptide CXO Market Size (US$ Million) & (2021-2032) Figure 11. Global Peptide CXO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Peptide CXO Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Peptide CXO Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Peptide CXO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide CXO Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide CXO Revenue Market Share by Type (2021-2032) Figure 18. Global Peptide CXO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide CXO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Peptide CXO Revenue Market Share by Application (2021-2032) Figure 21. North America Peptide CXO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Peptide CXO Revenue Share by Type (2021-2032) Figure 23. North America Peptide CXO Revenue Share by Application (2021-2032) Figure 24. North America Peptide CXO Revenue Share by Country (2021-2032) Figure 25. United States Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Peptide CXO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Peptide CXO Revenue Share by Type (2021-2032) Figure 30. Europe Peptide CXO Revenue Share by Application (2021-2032) Figure 31. Europe Peptide CXO Revenue Share by Country (2021-2032) Figure 32. Germany Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Peptide CXO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Peptide CXO Revenue Share by Type (2021-2032) Figure 42. China Peptide CXO Revenue Share by Application (2021-2032) Figure 43. Asia Peptide CXO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Peptide CXO Revenue Share by Type (2021-2032) Figure 45. Asia Peptide CXO Revenue Share by Application (2021-2032) Figure 46. Asia Peptide CXO Revenue Share by Region (2021-2032) Figure 47. Japan Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Peptide CXO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Peptide CXO Revenue Share by Type (2021-2032) Figure 55. SAMEA Peptide CXO Revenue Share by Application (2021-2032) Figure 56. SAMEA Peptide CXO Revenue Share by Country (2021-2032) Figure 57. Brazil Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Peptide CXO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • CRO
  • CMO/CDMO
Applications
  • Pharmaceutical Companies
  • Biotech Companies and Research Institutions
Companies covered
  • Chinese Peptide Company
  • WuXi AppTec
  • Shenzhen JYMed Technology
  • ReaLi Tide Biological Technology
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • LONZA
  • Asymchem
  • GL Biochem
  • Chengdu Shengnuo Biotechnology
  • AmbioPharm
  • Polypeptide
  • Pepscan
  • JPT Peptide
  • Bicycle
  • Bachem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide CXO Market by Type
  3. 1.2.1 Global Peptide CXO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CRO
  5. 1.2.3 CMO/CDMO
  6. 1.3 Peptide CXO Market by Application
  7. 1.3.1 Global Peptide CXO Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical Companies
  9. 1.3.3 Biotech Companies and Research Institutions
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Peptide CXO Market Dynamics
  1. 2.1 Peptide CXO Industry Trends
  2. 2.2 Peptide CXO Industry Drivers
  3. 2.3 Peptide CXO Industry Opportunities and Challenges
  4. 2.4 Peptide CXO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptide CXO Market Perspective (2021-2032)
  2. 3.2 Global Peptide CXO Growth Trends by Region
  3. 3.2.1 Global Peptide CXO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide CXO Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptide CXO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptide CXO Revenue by Players
  2. 4.1.1 Global Peptide CXO Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptide CXO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptide CXO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide CXO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptide CXO Key Players Headquarters & Area Served
  7. 4.4 Global Peptide CXO Players, Product Type & Application
  8. 4.5 Global Peptide CXO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptide CXO Market CR5 and HHI
  11. 4.6.3 2025 Peptide CXO Tier 1, Tier 2, and Tier 3
5 Peptide CXO Market Size by Type
  1. 5.1 Global Peptide CXO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide CXO Revenue by Type (2021-2032)
  3. 5.3 Global Peptide CXO Revenue Market Share by Type (2021-2032)
6 Peptide CXO Market Size by Application
  1. 6.1 Global Peptide CXO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptide CXO Revenue by Application (2021-2032)
  3. 6.3 Global Peptide CXO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Chinese Peptide Company
  2. 7.1.1 Chinese Peptide Company Company Information
  3. 7.1.2 Chinese Peptide Company Business Overview
  4. 7.1.3 Chinese Peptide Company Peptide CXO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Chinese Peptide Company Peptide CXO Product Portfolio
  6. 7.1.5 Chinese Peptide Company Recent Developments
  7. 7.2 WuXi AppTec
  8. 7.2.1 WuXi AppTec Company Information
  9. 7.2.2 WuXi AppTec Business Overview
  10. 7.2.3 WuXi AppTec Peptide CXO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 WuXi AppTec Peptide CXO Product Portfolio
  12. 7.2.5 WuXi AppTec Recent Developments
  13. 7.3 Shenzhen JYMed Technology
  14. 7.3.1 Shenzhen JYMed Technology Company Information
  15. 7.3.2 Shenzhen JYMed Technology Business Overview
  16. 7.3.3 Shenzhen JYMed Technology Peptide CXO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Shenzhen JYMed Technology Peptide CXO Product Portfolio
  18. 7.3.5 Shenzhen JYMed Technology Recent Developments
  19. 7.4 ReaLi Tide Biological Technology
  20. 7.4.1 ReaLi Tide Biological Technology Company Information
  21. 7.4.2 ReaLi Tide Biological Technology Business Overview
  22. 7.4.3 ReaLi Tide Biological Technology Peptide CXO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 ReaLi Tide Biological Technology Peptide CXO Product Portfolio
  24. 7.4.5 ReaLi Tide Biological Technology Recent Developments
  25. 7.5 Jiangsu Sinopep-Allsino Biopharmaceutical
  26. 7.5.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
  27. 7.5.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
  28. 7.5.3 Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Jiangsu Sinopep-Allsino Biopharmaceutical Peptide CXO Product Portfolio
  30. 7.5.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
  31. 7.6 LONZA
  32. 7.6.1 LONZA Company Information
  33. 7.6.2 LONZA Business Overview
  34. 7.6.3 LONZA Peptide CXO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 LONZA Peptide CXO Product Portfolio
  36. 7.6.5 LONZA Recent Developments
  37. 7.7 Asymchem
  38. 7.7.1 Asymchem Company Information
  39. 7.7.2 Asymchem Business Overview
  40. 7.7.3 Asymchem Peptide CXO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Asymchem Peptide CXO Product Portfolio
  42. 7.7.5 Asymchem Recent Developments
  43. 7.8 GL Biochem
  44. 7.8.1 GL Biochem Company Information
  45. 7.8.2 GL Biochem Business Overview
  46. 7.8.3 GL Biochem Peptide CXO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GL Biochem Peptide CXO Product Portfolio
  48. 7.8.5 GL Biochem Recent Developments
  49. 7.9 Chengdu Shengnuo Biotechnology
  50. 7.9.1 Chengdu Shengnuo Biotechnology Company Information
  51. 7.9.2 Chengdu Shengnuo Biotechnology Business Overview
  52. 7.9.3 Chengdu Shengnuo Biotechnology Peptide CXO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Chengdu Shengnuo Biotechnology Peptide CXO Product Portfolio
  54. 7.9.5 Chengdu Shengnuo Biotechnology Recent Developments
  55. 7.10 AmbioPharm
  56. 7.10.1 AmbioPharm Company Information
  57. 7.10.2 AmbioPharm Business Overview
  58. 7.10.3 AmbioPharm Peptide CXO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AmbioPharm Peptide CXO Product Portfolio
  60. 7.10.5 AmbioPharm Recent Developments
  61. 7.11 Polypeptide
  62. 7.11.1 Polypeptide Company Information
  63. 7.11.2 Polypeptide Business Overview
  64. 7.11.3 Polypeptide Peptide CXO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Polypeptide Peptide CXO Product Portfolio
  66. 7.11.5 Polypeptide Recent Developments
  67. 7.12 Pepscan
  68. 7.12.1 Pepscan Company Information
  69. 7.12.2 Pepscan Business Overview
  70. 7.12.3 Pepscan Peptide CXO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Pepscan Peptide CXO Product Portfolio
  72. 7.12.5 Pepscan Recent Developments
  73. 7.13 JPT Peptide
  74. 7.13.1 JPT Peptide Company Information
  75. 7.13.2 JPT Peptide Business Overview
  76. 7.13.3 JPT Peptide Peptide CXO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 JPT Peptide Peptide CXO Product Portfolio
  78. 7.13.5 JPT Peptide Recent Developments
  79. 7.14 Bicycle
  80. 7.14.1 Bicycle Company Information
  81. 7.14.2 Bicycle Business Overview
  82. 7.14.3 Bicycle Peptide CXO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Bicycle Peptide CXO Product Portfolio
  84. 7.14.5 Bicycle Recent Developments
  85. 7.15 Bachem
  86. 7.15.1 Bachem Company Information
  87. 7.15.2 Bachem Business Overview
  88. 7.15.3 Bachem Peptide CXO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bachem Peptide CXO Product Portfolio
  90. 7.15.5 Bachem Recent Developments
8 North America
  1. 8.1 North America Peptide CXO Revenue (2021-2032)
  2. 8.2 North America Peptide CXO Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptide CXO Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptide CXO Revenue by Type (2027-2032)
  5. 8.3 North America Peptide CXO Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptide CXO Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptide CXO Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptide CXO Revenue by Application (2027-2032)
  9. 8.5 North America Peptide CXO Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptide CXO Revenue by Country
  11. 8.6.1 North America Peptide CXO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptide CXO Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptide CXO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peptide CXO Revenue (2021-2032)
  2. 9.2 Europe Peptide CXO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptide CXO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptide CXO Revenue by Type (2027-2032)
  5. 9.3 Europe Peptide CXO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptide CXO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptide CXO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptide CXO Revenue by Application (2027-2032)
  9. 9.5 Europe Peptide CXO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptide CXO Revenue by Country
  11. 9.6.1 Europe Peptide CXO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptide CXO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptide CXO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peptide CXO Revenue (2021-2032)
  2. 10.2 China Peptide CXO Revenue by Type (2021-2032)
  3. 10.2.1 China Peptide CXO Revenue by Type (2021-2026)
  4. 10.2.2 China Peptide CXO Revenue by Type (2027-2032)
  5. 10.3 China Peptide CXO Revenue Share by Type (2021-2032)
  6. 10.4 China Peptide CXO Revenue by Application (2021-2032)
  7. 10.4.1 China Peptide CXO Revenue by Application (2021-2026)
  8. 10.4.2 China Peptide CXO Revenue by Application (2027-2032)
  9. 10.5 China Peptide CXO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide CXO Revenue (2021-2032)
  2. 11.2 Asia Peptide CXO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptide CXO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptide CXO Revenue by Type (2027-2032)
  5. 11.3 Asia Peptide CXO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptide CXO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptide CXO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptide CXO Revenue by Application (2027-2032)
  9. 11.5 Asia Peptide CXO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptide CXO Revenue by Country
  11. 11.6.1 Asia Peptide CXO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptide CXO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptide CXO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide CXO Revenue (2021-2032)
  2. 12.2 SAMEA Peptide CXO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptide CXO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptide CXO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptide CXO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptide CXO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptide CXO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptide CXO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptide CXO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptide CXO Revenue by Country
  11. 12.6.1 SAMEA Peptide CXO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptide CXO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptide CXO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst